Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000320 · ClinicalTrials.gov registry record · Phase 1
Buprenorphine Formulation Comparison: Sublingual Tablet vs. Solution - 1
A Phase 1 study, sponsored by National Institute on Drug Abuse (NIDA).
- Completed
- Registry status
- Phase 1
- Development phase
- 120
- Enrollment target
NCT00000320 is a Phase 1 study that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 120 participants.
The verdict
NCT00000320, a Phase 1 study, has completed, sponsored by National Institute on Drug Abuse (NIDA).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 120 participants
- Enrollment target
Study Summary
The purpose of this study is to compare subject response to liquid vs. tablet formulations, to assess bioequivalency of liquid vs. tablet, to compare subject preference, and to evaluate if dose response curve for tablet is equal to liquid form."
Interventions
- DRUG Buprenorphine formulation: liquid vs. tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 1997-10 |
| Est. Completion | 1999-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00000320
The ClinicalTrials.gov registry entry for NCT00000320 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute on Drug Abuse (NIDA), which has 335 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Buprenorphine formulation: liquid vs. tablet is the first listed.
NCT00000320 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00000320 about?
NCT00000320 is a clinical study titled "Buprenorphine Formulation Comparison: Sublingual Tablet vs. Solution - 1". The purpose of this study is to compare subject response to liquid vs. tablet formulations, to assess bioequivalency of liquid vs. tablet, to compare subject preference, and to evaluate if dose response curve for tablet is equal to liquid form."
What is the current status of trial NCT00000320?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 120 participants. The study started on 1997-10. Estimated completion is 1999-08.
What interventions are being tested in trial NCT00000320?
The interventions under investigation include: Buprenorphine formulation: liquid vs. tablet (DRUG).
Who is sponsoring clinical trial NCT00000320?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.